Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hypoxia × Circulating Tumor DNA × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 3 Glioblastoma 2 Vulvar Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Melanoma 1 Locally Advanced Rectal Carcinoma 1 Hypoxia 1 Gliosarcoma 1 Glioma 1 Genetic Diseases, Inborn 1 Esophageal Neoplasms 1 Circulating Tumor DNA 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

pimonidazole 4 TH 302 4 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 4 fluoroazomycin arabinoside 3 Propofol 3 Injections 3 Radiotherapy 2 pomalidomide 1 fluoromisonidazole 1 fludarabine 1 alovudine 1 Tirapazamine 1 Thoracotomy 1 Thoracic Surgery, Video-Assisted 1 Temozolomide 1 Sodium Chloride 1 Sevoflurane 1 Saline Solution 1 Oxygen 1 Nitroglycerin 1 Nimorazole 1 Magnetic Resonance Spectroscopy 1 Letrozole 1 Ketamine 1 Ipilimumab 1 Hydroxychloroquine 1 Furosemide 1 Ferrosoferric Oxide 1 Exercise 1 Ethiodized Oil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05702619 2023-01-27

HYPROGEN

The Christie NHS Foundation Trust

Hypoxia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡